Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Apr 29, 2021
- Full-year 2021 Financial Guidance ReaffirmedFinancial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended March 31, 2021 2020 % Change Total Revenues $ 486.0 $ 502.1 (3) % Net Product Revenues...
-
Apr 28, 2021The collaboration leverages technologies intended to target gene expression to specific cells within the central nervous system
The Allen Institute and BioMarin Pharmaceutical Inc. announced a collaboration today that will use technologies developed at the Allen Institute to create new gene therapies aimed at rare genetic...
-
Apr 15, 2021Normal Progression of Bone Age with Chronological Age Over 60 Months with Vosoritide for Children with Achondroplasia
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) presented new and updated data at the 2021 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting that demonstrates...
-
Apr 13, 2021
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday,...
-
Mar 20, 2021Height Gain is Maintained in 2nd Year of Treatment
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that data from the open-label long-term extension of the Phase 3 study of 15 µg/kg dose of vosoritide was presented at an oral...